Drug Profile

Siltartoxatug - Zhuhai Trinomab Pharmaceutical

Alternative Names: Sintetol; TNM-002; TT-069; Xintituo

Latest Information Update: 06 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Trinomab Biotech
Developer Zhuhai Trinomab Pharmaceutical
Class Antibacterials; Monoclonal antibodies
Mechanism of Action Tetanus toxin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Tetanus

Most Recent Events

28 May 2026 Zhuhai Trinomab Biopharmaceutical collaborates with Shanghai Pharmaceuticals Holding to commercialisation Siltartoxatug in Philippines for Tetanus
15 Dec 2025 Updated efficacy data from a phase IIII trial in Tetanus released by Zhuhai Trinomab Pharmaceutical
15 Dec 2025 Zhuhai Trinomab Pharmaceutical plans a phase III trial for Tetanus in the USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com